Falcó Vicenç, Burgos Joaquin, Papiol Elisabeth, Ferrer Ricard, Almirante Benito
a Infectious Diseases Department, University Hospital Vall d'Hebron , Universitat Autònoma de Barcelona , Barcelona , Spain.
b Intensive Care Department, University Hospital Vall d'Hebron , Universitat Autònoma de Barcelona , Barcelona , Spain.
Expert Opin Investig Drugs. 2016 Jun;25(6):653-65. doi: 10.1517/13543784.2016.1168803. Epub 2016 Apr 1.
Hospital acquired pneumonia (HAP) is one of the main infections acquired by patients during a stay in hospital. The main issue when dealing with patients with HAP and ventilator associated pneumonia (VAP) is the increasing role of multi-drug resistant organisms (MDROs).
In this review the authors summarize the actual situation of MDROs as a cause of HAP and VAP. They also review the current treatment options stated in the most important international guidelines. Finally, they focus on the investigational drugs that have reached the phase III stage of development and the novel compounds that are being studied in phase I and II clinical trials.
Thanks to their excellent activity against MDROs, drugs in development for the treatment of HAP and VAP can significantly improve the therapeutic options available. In selected patients, the possibility to administer directed therapy with monoclonal antibodies to specific pathogens is an exciting strategy in the fight against widespread resistance.
医院获得性肺炎（HAP）是患者住院期间获得的主要感染之一。处理HAP和呼吸机相关性肺炎（VAP）患者时的主要问题是多重耐药菌（MDROs）的作用日益增强。
在本综述中，作者总结了MDROs作为HAP和VAP病因的实际情况。他们还回顾了最重要的国际指南中所述的当前治疗选择。最后，他们重点关注已进入III期开发阶段的研究性药物以及正在I期和II期临床试验中研究的新型化合物。
由于其对MDROs具有出色的活性，正在开发用于治疗HAP和VAP的药物可显著改善可用的治疗选择。在选定的患者中，使用针对特定病原体的单克隆抗体进行定向治疗的可能性是对抗广泛耐药性的一项令人兴奋的策略。
